Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up (Q36295053)
scientific article published on January 1, 1998
Language:
(P31) (Q13442814)
(P304) 115-122
(P407) (Q1860)
(P433) 1
(P478) 77
(P577) Thursday, January 1, 1998
Thursday, January 1, 1998
(P921) (Q12859063)
(Q412178)
(P953) https://europepmc.org/articles/pmc2151275?pdf=render
https://europepmc.org/articles/PMC2151275
https://europepmc.org/articles/PMC2151275?pdf=render
http://www.nature.com/articles/bjc199818.pdf
http://www.nature.com/articles/bjc199818
(P1433) (Q326309)
(P1476) "Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up" (language: en)
(P2093) M. Bontenbal
J. A. Foekens
S. W. Lamberts
F. H. de Jong
W. L. van Putten
H. J. Braun
J. T. Burghouts
G. H. van der Linden
J. G. Klijn
(P2860) (Q40929319)
(Q36732238)
(Q40642391)
(Q34724374)
(Q34634036)
(Q34215127)
(Q36691246)
(Q40395035)
(Q39471065)
(Q35536048)
(Q38031520)
(Q37938852)
(Q37911390)
(Q33509065)
(Q33506131)
(Q37439630)
(Q34569188)
(Q35898237)
(Q33192976)
(Q35465195)
(Q41090546)
(Q28327480)
(Q41082661)
(Q41318787)
(Q41519206)
(Q42455264)
(Q41491680)
(Q42118641)
(Q46735809)
(Q42500788)
(Q42495085)
(Q42493841)
(Q44601066)
(Q49091725)
(Q51604520)
(Q48322967)
(Q44833988)
(Q69339469)
(Q69372214)
(Q69372864)
(Q72312399)
(Q71729075)
(Q67858417)
(Q67542391)
(Q70565385)
(Q72159523)
(Q69736401)
(Q66896349)
(Q72499908)
(Q71688407)
(Q60326256)
(Q72568526)
(Q70619679)
(Q93632560)
(Q63359361)
(Q69377991)
(Q68475529)
(Q68644618)
(Q68495434)
(Q67854780)
(Q72875199)
(Q70013603)
(Q69885770)
(Q69894126)
(Q68187815)
(Q70046632)
(Q70062828)
(Q70063206)
(Q70243607)
other details
description scientific article published on January 1, 1998

External Links